Tandem Therapeutics AG

Tandem Therapeutics is building the next generation of disease modifying antifibrotic drugs through extracellular matrix mechano-targeted peptide-drug conjugates (PDCs). Our proprietary peptides turn the fibrotic microenvironment, long considered a barrier to therapy - into a selective delivery system, enabling potent and safe treatments for progressive fibrosis.

Tandem’s platform integrates mechanobiology-informed peptide targeting with modular conjugation chemistry and controlled-release linkers, producing selective antifibrotic agents that can be potentially tuned for broader applications